Industry News

Gilead buys early-stage IL-12 asset from Xilio 

March 28, 2024
In a deal that could reach $648 million, Gilead bets on a phase 1 tumor-activated IL-12 program

Akebia snags FDA approval for anemia drug, finally

March 28, 2024
Vadadustat initially faced rejection in 2022, followed by an additional CRL in 2023

Blackstone backs Moderna flu program with $750M investment

March 27, 2024
With Moderna about to file its seasonal flu vaccine with regulators, Blackstone backs its mRNA tech

Bayer to let go of 90 workers at NJ site

March 27, 2024
The news follows shortly after the drugmaker announced major layoffs at its German facility

AbbVie to acquire Landos Biopharma

March 26, 2024
The acquisition centers on Landos' lead compound, an oral NLRX1 agonist currently in phase 2 clinical trials for ulcerative colitis and Crohn's disease

AstraZeneca expands Ultomiris into rare autoimmune disease

March 26, 2024
The approval makes the blockbuster the first and only long-acting C5 complement inhibitor for the treatment of neuromyelitis optica spectrum disorder

FDA rejects Regeneron lymphoma treatment

March 25, 2024
The agency did not raise concerns over the drug's efficacy, safety, trial design, labeling, or manufacturing processes

Novo Nordisk continues cardiovascular push with Cardior buy

March 25, 2024
In a deal that could reach $1.1 billion, Novo will add a phase 2 heart failure drug to its pipeline

J&J wins FDA nod for PAH combo tablet 

March 25, 2024
Opsynvi is a single-tablet combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension

Medicare to cover Wegovy for heart disease patients

March 22, 2024
The CMS has reportedly issued updated guidance for Medicare Part D plans

FDA approves Italfarmaco Duchenne drug

March 22, 2024
In the EPIDYS trial, Duvyzat significantly enhanced patient mobility and muscle function

Idorsia grabs FDA approval for hypertension drug

March 21, 2024
Just months after J&J handed the rights to the drug back to the Swiss biotech, Tryvio wins approval to treat high blood pressure

Novo Nordisk invests $580M in China site expansion

March 21, 2024
The investment aims to expand the production of sterile preparations, with completion targeted for 2027

Orchard $4.3M gene therapy becomes most expensive in the world

March 20, 2024
Lenmeldy, which snagged FDA approval on Monday, knocked CSL's $3.5 million hemophilia B gene therapy to second place

Lonza pays $1.2B for Genentech biologics site

March 20, 2024
The CDMO will take over one of the largest biologics manufacturing sites in the world

AstraZeneca bets on radioconjugates with $2.4B Fusion buy

March 19, 2024
Included in the acquisition is Fusion’s phase 2 treatment for metastatic castration-resistant prostate cancer

Orchard gene therapy wins first FDA nod for rare pediatric disease

March 19, 2024
Lenmeldy becomes the first therapy approved for early-onset metachromatic leukodystrophy in the U.S.

AdComm backs earlier use of CAR-T for multiple myeloma

March 18, 2024
The Oncologic Drugs Advisory Committee voted in favor of expanding the use of J&J and Legend's Carvykti and Bristol Myers Squibb and 2seventy bio's Abecma

Novartis announces Singapore site expansion

March 18, 2024
The $256 million expanded facility, with a focus on therapeutic antibody drugs, is expected to be operational by early 2026

FDA approves BeiGene esophageal cancer drug

March 15, 2024
The nod marks the first U.S. indication for Tevimbra, expected to be available in the latter half of 2024

Madrigal wins first FDA nod for NASH

March 14, 2024
Rezdiffra becomes the first and only treatment for the severe form of fatty liver disease

BIO backs BIOSECURE Act, boots WuXi

March 14, 2024
The industry's largest biotech trade association is removing WuXi AppTec from its membership roster

AstraZeneca to acquire Amolyt Pharma

March 14, 2024
The potential $1.05 billion deal will boost AstraZeneca's rare disease portfolio

Amazon Pharmacy to deliver Eli Lilly drugs

March 13, 2024
The partnership will facilitate access to specific prescriptions for obesity, diabetes, and migraines through a direct sales platform

Novartis buys IFM unit, picking up STING inhibitors 

March 13, 2024
In a deal that could reach $835 million, Novartis will pick up a portfolio of STING antagonists targeting serious inflammation-driven diseases

Merck, Pearl Bio ink programmable biologics partnership

March 12, 2024
The potential $1 billion deal will pave the road for new classes of multi-functionalized biologics with tunable properties

Acadia abandons plans to expand pimavanserin indications 

March 12, 2024
The drugmaker has halted efforts to expand the label on its lead drug following a phase 3 trial flop in schizophrenia

Boehringer, Sosei Heptares partner on schizophrenia treatments

March 11, 2024
In the deal, which could exceed $760 million, Boehringer has the exclusive option to license Sosei's GPR52 agonists

Incyte JAK1 inhibitor shines in phase 2 trial

March 11, 2024
The drug significantly improved itch relief across various dosage groups compared to placebo

Amylyx ALS drug falls short in phase 3 trial

March 8, 2024
The company is contemplating a potential market withdrawal, pending discussions with regulatory bodies